ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RCPT (MM)

231.96
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:RCPT NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 231.96 0.00 01:00:00

Receptos to Present at Jefferies 2013 Global Healthcare Conference

29/05/2013 9:30pm

GlobeNewswire Inc.


RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more RECEPTOS, INC. Charts.

Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its President and Chief Executive Officer, Faheem Hasnain, will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt Hotel in New York City. The presentation is scheduled for Wednesday, June 5, 2013, at 9:30 am Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@receptos.com

1 Year RECEPTOS, INC. Chart

1 Year RECEPTOS, INC. Chart

1 Month RECEPTOS, INC. Chart

1 Month RECEPTOS, INC. Chart

Your Recent History

Delayed Upgrade Clock